Atherosclerosis: Diet and Drugs

  • Arnold von Eckardstein

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 170)

Table of contents

  1. Front Matter
    Pages I-XII
  2. Background

    1. P. Cullen, J. Rauterberg, S. Lorkowski
      Pages 3-70
    2. A. von Eckardstein
      Pages 71-105
  3. The Impact of Diet

    1. T.A. Lakka, C. Bouchard
      Pages 137-163
    2. M.A. Thijssen, R.P. Mensink
      Pages 165-194
    3. M.J. Tikkanen
      Pages 215-230
    4. P.M. Suter
      Pages 231-261
    5. M. Aviram, M. Kaplan, M. Rosenblat, B. Fuhrman
      Pages 263-300
    6. R. St. Clair, M. Anthony
      Pages 301-323
    7. S. Cook, O.M. Hess
      Pages 325-338
    8. H.F.J. Hendriks, A. van Tol
      Pages 339-361
  4. Evidence-Based Anti-Atherosclerotic Drug Therapy

    1. R. Paoletti, C. Bolego, A. Cignarella
      Pages 365-388
    2. R. Robillard, C. Fontaine, G. Chinetti, J.-C. Fruchart, B. Staels
      Pages 389-406
    3. A. Dendorfer, P. Dominiak, H. Schunkert
      Pages 407-442
    4. I. Ahrens, C. Bode, K. Peter
      Pages 443-462
  5. Targets of Future Anti-Atherosclerotic Drug Therapy

    1. T. Plösch, A. Kosters, A.K. Groen, F. Kuipers
      Pages 465-482
    2. K.M. Kostner, G.M. Kostner
      Pages 519-536
    3. O. Cynshi, R. Stocker
      Pages 563-590
    4. D. Müller-Wieland, J. Kotzka
      Pages 591-617
    5. L.E. Spieker, T.F. Lüscher
      Pages 619-644
    6. S. Bellosta, F. Bernini
      Pages 665-695
    7. K. Mandal, M. Jahangiri, Q. Xu
      Pages 723-743
    8. P.T. Kovanen, M. Mäyränpää, K.A. Lindstedt
      Pages 745-776
    9. T. Murayama, O.M. Tepper, T. Asahara
      Pages 777-783
    10. E. Vähäkangas, S. Ylä-Herttuala
      Pages 785-807
  6. Back Matter
    Pages 809-816

About this book


Cardiovascular diseases continue to be the leading cause of death in the - jority of industrialized countries. The most frequent underlying pathology, namely atherosclerosis, and its clinical sequelae, namely coronary heart d- ease, cerebrovascular disease and peripheral artery disease, remain common although for a long time we have been made aware of avoidable or mo- ?able etiological factors such as smoking, fat-rich diet or lack of exercise, and although these adverse lifestyle factors have been extensively addressed by population-wide primary prevention programs. Cardiovascular morbidity and mortality also remain high despite successful anti-hypertensive and lipid lowering drug therapies which help to reduce cardiovascular morbidity and mortality by about 30% in both secondary and tertiary prevention settings. This can partly be explained by the increasing life expectancy and growing p- portionofelderly people,especiallyinEuropeandNorthAmerica. Inaddition, the World Health Organization makes the alarming prediction that probably in response to the spreading of western dietary behavior and lack of exercise resulting in an increasing prevalence of diabetes, dyslipidemia and hypert- sion, cardiovascular diseases rather than infectious diseases will become the most frequent cause of death worldwide. This volume of the Handbook of Experimental Pharmacology entitled “Atherosclerosis” is divided into four parts and intends to give an overview on the pathogenesis of atherosclerosis, established treatment and prevention regimen, and of perspectives for the development of new treatment modalities.


Angiotensin II atherosclerosis cardiovascular gene therapy heart disease prevention risk factors vascular biology

Editors and affiliations

  • Arnold von Eckardstein
    • 1
  1. 1.Institute of Clinical ChemistryUniversity Hospital of ZurichZürichSwitzerland

Bibliographic information

Industry Sectors
Health & Hospitals
Internal Medicine & Dermatology